\-\ Texto\\:\\ \ \(0\)\
\-\ physical\\ exam\\:\\ \\ \ \(0\)\
\-\ no\\ abnormalities\\.\ \(11\)\
\-\ labs\\:\ \(4\)\
\-\ fungal\\,\\ acid\\-fast\\,\\ and\\ gram\\ stains\\ showed\\ no\\ \\ organisms\\.\\ \\ \ \(0\)\
\-\ pleural\\ fluid\\ analysis\\ was\\ suspicious\\ for\\ malignancy\\.\ \(0\)\
\-\ histopathologic\\ analysis\\ of\\ tissue\\ samples\\ of\\ all\\ three\\ right\\ lung\\ lobes\\ including\\ mediastinal\\ lymph\\ nodes\\ revealed\\ extensive\\ lymphovascular\\ invasion\\,\\ focal\\ areas\\ of\\ necrosis\\,\\ and\\ several\\ areas\\ with\\ signet\\-ring\\ cells\\.\ \(0\)\
\-\ the\\ patient\\ was\\ initially\\ treated\\ for\\ pneumonia\\ based\\ on\\ her\\ symptoms\\ and\\ the\\ findings\\ on\\ chest\\ x\\-ray\\.\\ \\ further\\ evaluation\\ was\\ completed\\ after\\ recurrence\\ of\\ symptoms\\ within\\ one\\ month\\ of\\ therapy\\.\\ \\ vats\\ and\\ mediastinoscopy\\ were\\ performed\\ after\\ bronchoalveolar\\ lavage\\ yielded\\ cells\\ suspicious\\ for\\ malignancy\\.\\ \\ a\\ whole\\ body\\ pet\\ scan\\ and\\ brain\\ mri\\ were\\ performed\\ and\\ did\\ not\\ reveal\\ any\\ evidence\\ of\\ distant\\ metastases\\.\\ \\ chemotherapy\\ was\\ initiated\\ and\\ the\\ patient\\ later\\ underwent\\ a\\ right\\-sided\\ pneumonectomy\\.\ \(0\)\
\-\ chest\\ pa\\/lat\\ revealed\\ increased\\ interstitial\\ markings\\ in\\ the\\ right\\ lower\\ lobe\\.\ \(0\)\
\-\ contrast\\ enhanced\\ chest\\ ct\\ revealed\\ diffuse\\ increased\\ interstitial\\ markings\\ involving\\ the\\ right\\ middle\\ and\\ lower\\ lobes\\,\\ pleural\\ thickening\\/scarring\\ of\\ the\\ posterior\\ right\\ lower\\ lobe\\,\\ and\\ a\\ small\\ right\\-sided\\ pleural\\ effusion\\.\ \(0\)\
\-\ adenocarcinoma\\ of\\ the\\ lung\ \(5\)\
\-\ lymphangitic\\ spread\\ of\\ malignancy\ \(3\)\
\-\ primary\\ malignancy\ \(8\)\
\-\ lymphoma\ \(373\)\
\-\ sjogrens\\ syndrome\ \(0\)\
\-\ lymphangioleiomyomatosis\ \(13\)\
\-\ pneumonia\\ \\(bacterial\\,\\ atypical\\,\\ viral\\)\ \(1\)\
\-\ collagen\\ vascular\\ disease\\ \\(sle\\,\\ ra\\)\ \(0\)\
\-\ hypersensitivity\\ pneumonitis\ \(9\)\
\-\ asbestosis\ \(10\)\
\-\ edema\\ \\(secondary\\ to\\ fluid\\ overload\\,\\ chf\\,\\ or\\ nephrotic\\ syndrome\\)\ \(0\)\
\-\ the\\ patient\\ is\\ a\\ 43\\-year\\-old\\ female\\ who\\ presented\\ with\\ a\\ 6\\-month\\ history\\ of\\ progressively\\ worsening\\ shortness\\ of\\ breath\\ with\\ exertion\\ during\\ her\\ 5\\-mile\\ runs\\.\\ \\ the\\ patient\\ also\\ complained\\ of\\ wheezing\\ but\\ denied\\ having\\ a\\ cough\\,\\ fevers\\,\\ chills\\,\\ or\\ weight\\ loss\\.\\ \\ this\\ patient\\ does\\ not\\ have\\ a\\ previous\\ history\\ of\\ any\\ chronic\\ illnesses\\ and\\ does\\ not\\ have\\ any\\ history\\ of\\ tobacco\\ use\\.\ \(0\)\
\-\ lung\\ cancer\\ must\\ be\\ ruled\\ out\\ in\\ any\\ patient\\ with\\ a\\ nonresolving\\ pneumonia\\.\\ \\ lung\\ cancer\\ has\\ surpassed\\ breast\\ cancer\\ in\\ becoming\\ the\\ leading\\ cause\\ of\\ cancer\\ death\\ in\\ women\\.\\ adenocarcinoma\\ accounts\\ for\\ 30\\-40\\%\\ of\\ lung\\ cancers\\ and\\ is\\ the\\ most\\ common\\ histologic\\ type\\.\\ \\ it\\ is\\ also\\ the\\ most\\ common\\ type\\ of\\ lung\\ cancer\\ in\\ non\\-smokers\\ \\(an\\ estimated\\ 10\\-15\\%\\ of\\ patients\\ diagnosed\\ with\\ lung\\ cancer\\ are\\ non\\-smokers\\)\\.\\ \\ the\\ most\\ common\\ sites\\ of\\ distant\\ metastases\\ are\\ the\\ brain\\,\\ bones\\ \\(most\\ commonly\\ vertebrae\\)\\,\\ liver\\,\\ adrenals\\,\\ and\\ skin\\.\\ \\ the\\ american\\ thoracic\\ society\\ recommends\\ measurement\\ of\\ a\\ cbc\\,\\ serum\\ electrolytes\\,\\ calcium\\,\\ alkaline\\ phosphatase\\,\\ albumin\\,\\ ast\\,\\ alt\\,\\ total\\ bilirubin\\,\\ and\\ creatinine\\ in\\ all\\ patients\\ with\\ lung\\ cancer\\.\\ \\ abnormal\\ lfts\\ should\\ be\\ followed\\ up\\ with\\ a\\ contrast\\-enhanced\\ ct\\ of\\ the\\ liver\\,\\ and\\ an\\ elevated\\ alkaline\\ phosphatase\\ or\\ calcium\\ level\\ should\\ be\\ followed\\ up\\ with\\ a\\ bone\\ or\\ pet\\ scan\\ to\\ detect\\ metastases\\ \\(there\\ is\\ conflicting\\ evidence\\ as\\ to\\ which\\ imaging\\ modality\\ has\\ greater\\ sensitivity\\)\\.\\ \\ stage\\ iv\\ disease\\ is\\ primarily\\ managed\\ with\\ chemotherapy\\ or\\ with\\ palliative\\ measures\\ for\\ symptomatic\\ relief\\,\\ and\\ the\\ five\\ year\\ survival\\ rate\\ is\\ less\\ than\\ 5\\%\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ lung\\:\\ 0\\.2404084209943952\ \(0\)\
\-\ cancer\\:\\ 0\\.23033078889165406\ \(0\)\
\-\ of\\:\\ 0\\.2030177070270218\ \(0\)\
\-\ the\\:\\ 0\\.16757310414975712\ \(0\)\
\-\ and\\:\\ 0\\.153120930229029\ \(0\)\
\-\ malignancy\\:\\ 0\\.1479326506564816\ \(0\)\
\-\ any\\:\\ 0\\.1277069017637196\ \(0\)\
\-\ metastases\\:\\ 0\\.11981327794227713\ \(0\)\
\-\ pneumonia\\:\\ 0\\.11697622474924935\ \(0\)\
\-\ phosphatase\\:\\ 0\\.11357934278541115\ \(0\)\
\-\ pleural\\:\\ 0\\.11156565542675037\ \(0\)\
\-\ alkaline\\:\\ 0\\.1111007876100052\ \(0\)\
\-\ distant\\:\\ 0\\.10332481744037096\ \(0\)\
\-\ most\\:\\ 0\\.10283860342819004\ \(0\)\
\-\ markings\\:\\ 0\\.09909524321217618\ \(0\)\
\-\ right\\:\\ 0\\.09827037343716344\ \(0\)\
\-\ revealed\\:\\ 0\\.0971754382305308\ \(0\)\
\-\ with\\:\\ 0\\.09673286193266381\ \(0\)\
\-\ patient\\:\\ 0\\.09640552137438453\ \(0\)\
\-\ analysis\\:\\ 0\\.09188106302601377\ \(0\)\
\-\ pet\\:\\ 0\\.09150451907966066\ \(0\)\
\-\ interstitial\\:\\ 0\\.0895682539897531\ \(0\)\
\-\ calcium\\:\\ 0\\.08923833278855246\ \(0\)\
\-\ suspicious\\:\\ 0\\.08828467876233048\ \(0\)\
\-\ or\\:\\ 0\\.08592822186168038\ \(0\)\
\-\ common\\:\\ 0\\.08404766611266191\ \(0\)\
\-\ lobes\\:\\ 0\\.08243478724472975\ \(0\)\
\-\ is\\:\\ 0\\.08117240072208673\ \(0\)\
\-\ adenocarcinoma\\:\\ 0\\.08075392124262738\ \(0\)\
\-\ lymphovascular\\:\\ 0\\.07900256805652196\ \(0\)\
\-\ mediastinoscopy\\:\\ 0\\.07900256805652196\ \(0\)\
\-\ sjogrens\\:\\ 0\\.07900256805652196\ \(0\)\
\-\ surpassed\\:\\ 0\\.07900256805652196\ \(0\)\
\-\ chest\\:\\ 0\\.07822867165368011\ \(0\)\
\-\ cells\\:\\ 0\\.07612517477862894\ \(0\)\
\-\ lower\\:\\ 0\\.07573152530519801\ \(0\)\
\-\ nonresolving\\:\\ 0\\.07549117141978551\ \(0\)\
\-\ enhanced\\:\\ 0\\.07522909534071023\ \(0\)\
\-\ for\\:\\ 0\\.07486495443685214\ \(0\)\
\-\ in\\:\\ 0\\.0737358333375478\ \(0\)\
\-\ pneumonectomy\\:\\ 0\\.07299979585760746\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.0701556141012557\ \(0\)\
\-\ nephrotic\\:\\ 0\\.069488399220871\ \(0\)\
\-\ adrenals\\:\\ 0\\.069488399220871\ \(0\)\
\-\ conflicting\\:\\ 0\\.069488399220871\ \(0\)\
\-\ was\\:\\ 0\\.06886661426741766\ \(0\)\
\-\ does\\:\\ 0\\.06830360760050158\ \(0\)\
\-\ liver\\:\\ 0\\.0681578535339246\ \(0\)\
\-\ recommends\\:\\ 0\\.06815342817682328\ \(0\)\
\-\ areas\\:\\ 0\\.06707937855009996\ \(0\)\
\-\ samples\\:\\ 0\\.06699702365869295\ \(0\)\
\-\ followed\\:\\ 0\\.0667194624438098\ \(0\)\
\-\ type\\:\\ 0\\.06627983632093822\ \(0\)\
\-\ runs\\:\\ 0\\.06506456264065358\ \(0\)\
\-\ should\\:\\ 0\\.06446798414377887\ \(0\)\
\-\ vats\\:\\ 0\\.06423916031103469\ \(0\)\
\-\ histopathologic\\:\\ 0\\.06348562702195648\ \(0\)\
\-\ overload\\:\\ 0\\.062150655977908774\ \(0\)\
\-\ illnesses\\:\\ 0\\.062150655977908774\ \(0\)\
\-\ her\\:\\ 0\\.061725583571325425\ \(0\)\
\-\ brain\\:\\ 0\\.06159260526464484\ \(0\)\
\-\ lavage\\:\\ 0\\.061553166003917116\ \(0\)\
\-\ lymphangioleiomyomatosis\\:\\ 0\\.061553166003917116\ \(0\)\
\-\ bronchoalveolar\\:\\ 0\\.060994251459778444\ \(0\)\
\-\ society\\:\\ 0\\.060994251459778444\ \(0\)\
\-\ asbestosis\\:\\ 0\\.06046923194788283\ \(0\)\
\-\ be\\:\\ 0\\.06011973885187709\ \(0\)\
\-\ month\\:\\ 0\\.0601021052485988\ \(0\)\
\-\ yielded\\:\\ 0\\.05997423038522002\ \(0\)\
\-\ becoming\\:\\ 0\\.05997423038522002\ \(0\)\
\-\ syndrome\\:\\ 0\\.05956360572946017\ \(0\)\
\-\ all\\:\\ 0\\.058814189627877954\ \(0\)\
\-\ stains\\:\\ 0\\.058639259341172305\ \(0\)\
\-\ electrolytes\\:\\ 0\\.058639259341172305\ \(0\)\
\-\ scan\\:\\ 0\\.05861784359719434\ \(0\)\
\-\ not\\:\\ 0\\.058506733477876036\ \(0\)\
\-\ performed\\:\\ 0\\.05845130058936102\ \(0\)\
\-\ lymphangitic\\:\\ 0\\.057482854823041975\ \(0\)\
\-\ hypersensitivity\\:\\ 0\\.0571293294236997\ \(0\)\
\-\ pneumonitis\\:\\ 0\\.0571293294236997\ \(0\)\
\-\ lfts\\:\\ 0\\.0571293294236997\ \(0\)\
\-\ lobe\\:\\ 0\\.057096837107326985\ \(0\)\
\-\ fluid\\:\\ 0\\.0570458198705418\ \(0\)\
\-\ measurement\\:\\ 0\\.056789671392705576\ \(0\)\
\-\ history\\:\\ 0\\.05662184923602198\ \(0\)\
\-\ evidence\\:\\ 0\\.05607988949317179\ \(0\)\
\-\ albumin\\:\\ 0\\.05584398699502964\ \(0\)\
\-\ patients\\:\\ 0\\.05558125721399996\ \(0\)\
\-\ histologic\\:\\ 0\\.055266428375481305\ \(0\)\
\-\ accounts\\:\\ 0\\.05499147926086393\ \(0\)\
\-\ chf\\:\\ 0\\.05421542276095489\ \(0\)\
\-\ symptoms\\:\\ 0\\.054058593751074226\ \(0\)\
\-\ initiated\\:\\ 0\\.05397145818630551\ \(0\)\
\-\ increased\\:\\ 0\\.0534271627323717\ \(0\)\
\-\ organisms\\:\\ 0\\.05327827475596911\ \(0\)\
\-\ detect\\:\\ 0\\.05327827475596911\ \(0\)\
\-\ palliative\\:\\ 0\\.05327827475596911\ \(0\)\
\-\ cancers\\:\\ 0\\.05305901824282456\ \(0\)\
\-\ bilirubin\\:\\ 0\\.05305901824282456\ \(0\)\
\-\ gram\\:\\ 0\\.0526364871422578\ \(0\)\
\-\ sle\\:\\ 0\\.05243270904196106\ \(0\)\
\-\ tobacco\\:\\ 0\\.05243270904196106\ \(0\)\
\-\ whole\\:\\ 0\\.051848656106635596\ \(0\)\
\-\ exertion\\:\\ 0\\.051848656106635596\ \(0\)\
\-\ estimated\\:\\ 0\\.051301516098210084\ \(0\)\
\-\ completed\\:\\ 0\\.05112655722478519\ \(0\)\
\-\ wheezing\\:\\ 0\\.05112655722478519\ \(0\)\
\-\ vertebrae\\:\\ 0\\.05112655722478519\ \(0\)\
\-\ were\\:\\ 0\\.05092932753977872\ \(0\)\
\-\ creatinine\\:\\ 0\\.050301154895166296\ \(0\)\
\-\ collagen\\:\\ 0\\.050145111580079754\ \(0\)\
\-\ sensitivity\\:\\ 0\\.050145111580079754\ \(0\)\
\-\ ruled\\:\\ 0\\.04940447504644973\ \(0\)\
\-\ have\\:\\ 0\\.04935677755898665\ \(0\)\
\-\ up\\:\\ 0\\.04887338787750733\ \(0\)\
\-\ ra\\:\\ 0\\.04885443817575169\ \(0\)\
\-\ modality\\:\\ 0\\.04885443817575169\ \(0\)\
\-\ death\\:\\ 0\\.048463687550053806\ \(0\)\
\-\ progressively\\:\\ 0\\.04833725946989913\ \(0\)\
\-\ managed\\:\\ 0\\.04833725946989913\ \(0\)\
\-\ sites\\:\\ 0\\.04821265056204038\ \(0\)\
\-\ survival\\:\\ 0\\.04821265056204038\ \(0\)\
\-\ contrast\\:\\ 0\\.048005640225369274\ \(0\)\
\-\ after\\:\\ 0\\.0479302359296704\ \(0\)\
\-\ complained\\:\\ 0\\.04761516058804872\ \(0\)\
\-\ alt\\:\\ 0\\.047500454676904266\ \(0\)\
\-\ ast\\:\\ 0\\.04738724823242149\ \(0\)\
\-\ primarily\\:\\ 0\\.04738724823242149\ \(0\)\
\-\ also\\:\\ 0\\.04647340238952602\ \(0\)\
\-\ relief\\:\\ 0\\.04632981815937867\ \(0\)\
\-\ bacterial\\:\\ 0\\.046230843714291155\ \(0\)\
\-\ viral\\:\\ 0\\.04556799365886489\ \(0\)\
\-\ has\\:\\ 0\\.04512965449564714\ \(0\)\
\-\ chills\\:\\ 0\\.04495229091331734\ \(0\)\
\-\ denied\\:\\ 0\\.04461916639427623\ \(0\)\
\-\ five\\:\\ 0\\.04461916639427623\ \(0\)\
\-\ women\\:\\ 0\\.04445728935065453\ \(0\)\
\-\ spread\\:\\ 0\\.044377471553536565\ \(0\)\
\-\ serum\\:\\ 0\\.04429838269625178\ \(0\)\
\-\ fungal\\:\\ 0\\.04422000958504641\ \(0\)\
\-\ invasion\\:\\ 0\\.04406535958822898\ \(0\)\
\-\ leading\\:\\ 0\\.04391342288968171\ \(0\)\
\-\ fevers\\:\\ 0\\.04361731986926963\ \(0\)\
\-\ having\\:\\ 0\\.04258921650790623\ \(0\)\
\-\ must\\:\\ 0\\.042334487270984614\ \(0\)\
\-\ american\\:\\ 0\\.04214823988453451\ \(0\)\
\-\ nodes\\:\\ 0\\.041965913788476486\ \(0\)\
\-\ reveal\\:\\ 0\\.041554845521724865\ \(0\)\
\-\ disease\\:\\ 0\\.04147336722085974\ \(0\)\
\-\ cbc\\:\\ 0\\.04121739362236487\ \(0\)\
\-\ recurrence\\:\\ 0\\.04078698605951533\ \(0\)\
\-\ atypical\\:\\ 0\\.04052845433309993\ \(0\)\
\-\ total\\:\\ 0\\.04047766140343133\ \(0\)\
\-\ measures\\:\\ 0\\.0402774173450865\ \(0\)\
\-\ mediastinal\\:\\ 0\\.03989030621079875\ \(0\)\
\-\ bones\\:\\ 0\\.039749487340915816\ \(0\)\
\-\ shortness\\:\\ 0\\.039610921669870354\ \(0\)\
\-\ stage\\:\\ 0\\.039340269340100716\ \(0\)\
\-\ initially\\:\\ 0\\.03873981913033148\ \(0\)\
\-\ lymph\\:\\ 0\\.03841451629686811\ \(0\)\
\-\ extensive\\:\\ 0\\.03806258738931447\ \(0\)\
\-\ symptomatic\\:\\ 0\\.037986285841253284\ \(0\)\
\-\ use\\:\\ 0\\.03779842229921708\ \(0\)\
\-\ an\\:\\ 0\\.03778136875590934\ \(0\)\
\-\ necrosis\\:\\ 0\\.037761333721403625\ \(0\)\
\-\ worsening\\:\\ 0\\.03772440330431709\ \(0\)\
\-\ ct\\:\\ 0\\.037614665453968306\ \(0\)\
\-\ are\\:\\ 0\\.03749068253826317\ \(0\)\
\-\ rate\\:\\ 0\\.037434496077181606\ \(0\)\
\-\ previous\\:\\ 0\\.03732823499331085\ \(0\)\
\-\ to\\:\\ 0\\.037050278060654675\ \(0\)\
\-\ thoracic\\:\\ 0\\.03691576800739558\ \(0\)\
\-\ cough\\:\\ 0\\.03688226634208419\ \(0\)\
\-\ skin\\:\\ 0\\.03674954083718671\ \(0\)\
\-\ effusion\\:\\ 0\\.036683933177322346\ \(0\)\
\-\ commonly\\:\\ 0\\.036554190380896745\ \(0\)\
\-\ greater\\:\\ 0\\.03639469840192327\ \(0\)\
\-\ breath\\:\\ 0\\.036207106164211356\ \(0\)\
\-\ breast\\:\\ 0\\.03587339809544576\ \(0\)\
\-\ abnormalities\\:\\ 0\\.035784575063644596\ \(0\)\
\-\ based\\:\\ 0\\.035784575063644596\ \(0\)\
\-\ diagnosed\\:\\ 0\\.035784575063644596\ \(0\)\
\-\ did\\:\\ 0\\.03543812207766636\ \(0\)\
\-\ including\\:\\ 0\\.03535363194718286\ \(0\)\
\-\ later\\:\\ 0\\.03535363194718286\ \(0\)\
\-\ middle\\:\\ 0\\.0353256507606984\ \(0\)\
\-\ iv\\:\\ 0\\.0352977596909126\ \(0\)\
\-\ involving\\:\\ 0\\.034602434509685365\ \(0\)\
\-\ weight\\:\\ 0\\.03444960401959688\ \(0\)\
\-\ labs\\:\\ 0\\.034225299316462135\ \(0\)\
\-\ underwent\\:\\ 0\\.03403068057152261\ \(0\)\
\-\ elevated\\:\\ 0\\.033677155172180326\ \(0\)\
\-\ cause\\:\\ 0\\.03365409212344195\ \(0\)\
\-\ less\\:\\ 0\\.03360814947095584\ \(0\)\
\-\ three\\:\\ 0\\.03316165009077648\ \(0\)\
\-\ showed\\:\\ 0\\.032904398413093436\ \(0\)\
\-\ vascular\\:\\ 0\\.03261362199644721\ \(0\)\
\-\ body\\:\\ 0\\.03251209481156731\ \(0\)\
\-\ out\\:\\ 0\\.032471814879960995\ \(0\)\
\-\ several\\:\\ 0\\.032411744097953596\ \(0\)\
\-\ further\\:\\ 0\\.032175543010765376\ \(0\)\
\-\ no\\:\\ 0\\.03212912935260557\ \(0\)\
\-\ during\\:\\ 0\\.03129033021200237\ \(0\)\
\-\ diffuse\\:\\ 0\\.030980390465205884\ \(0\)\
\-\ treated\\:\\ 0\\.03076324850943552\ \(0\)\
\-\ year\\:\\ 0\\.030448682549861827\ \(0\)\
\-\ primary\\:\\ 0\\.03037613737514777\ \(0\)\
\-\ evaluation\\:\\ 0\\.030127354172360586\ \(0\)\
\-\ loss\\:\\ 0\\.030096752834219375\ \(0\)\
\-\ level\\:\\ 0\\.029840916880489708\ \(0\)\
\-\ on\\:\\ 0\\.029839754276072102\ \(0\)\
\-\ abnormal\\:\\ 0\\.029679314453401235\ \(0\)\
\-\ focal\\:\\ 0\\.02954930112389584\ \(0\)\
\-\ edema\\:\\ 0\\.02946369743166682\ \(0\)\
\-\ lymphoma\\:\\ 0\\.02942121082306754\ \(0\)\
\-\ chronic\\:\\ 0\\.029322878561783887\ \(0\)\
\-\ secondary\\:\\ 0\\.02928107556983691\ \(0\)\
\-\ presented\\:\\ 0\\.028807724442657775\ \(0\)\
\-\ therapy\\:\\ 0\\.0283839399706896\ \(0\)\
\-\ one\\:\\ 0\\.0282842534635661\ \(0\)\
\-\ than\\:\\ 0\\.02800388569511557\ \(0\)\
\-\ who\\:\\ 0\\.027944118931447597\ \(0\)\
\-\ bone\\:\\ 0\\.02695459377796943\ \(0\)\
\-\ physical\\:\\ 0\\.026786225516265035\ \(0\)\
\-\ imaging\\:\\ 0\\.025961770636970697\ \(0\)\
\-\ tissue\\:\\ 0\\.02591452464044936\ \(0\)\
\-\ posterior\\:\\ 0\\.025545558522224576\ \(0\)\
\-\ small\\:\\ 0\\.025482575192371414\ \(0\)\
\-\ mri\\:\\ 0\\.025357966284512666\ \(0\)\
\-\ it\\:\\ 0\\.025287558013087862\ \(0\)\
\-\ exam\\:\\ 0\\.024868366738896072\ \(0\)\
\-\ but\\:\\ 0\\.024428752471271017\ \(0\)\
\-\ findings\\:\\ 0\\.024381255991980058\ \(0\)\
\-\ female\\:\\ 0\\.023838144681575198\ \(0\)\
\-\ within\\:\\ 0\\.022752466206221296\ \(0\)\
\-\ which\\:\\ 0\\.022463016585958298\ \(0\)\
\-\ as\\:\\ 0\\.019846038101525833\ \(0\)\
\-\ there\\:\\ 0\\.019656408652235155\ \(0\)\
\-\ this\\:\\ 0\\.01697499039261267\ \(0\)\
